Nafarelin (BioDeep_00000016485)
代谢物信息卡片
(D-2-Nal6)-LHRH acetate salt
化学式: C66H83N17O13 (1321.6355948)
中文名称: 那法瑞林
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
InChI: InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1
描述信息
H - Systemic hormonal preparations, excl. sex hormones and insulins > H01 - Pituitary and hypothalamic hormones and analogues > H01C - Hypothalamic hormones > H01CA - Gonadotropin-releasing hormones
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1910 - Gonadotropin-releasing Hormone Analog
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
D012102 - Reproductive Control Agents > D005299 - Fertility Agents
同义名列表
3 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:7445
- KEGG: C76463
- PubChem: 25077405
- DrugBank: DB00666
- MeSH: Nafarelin
- CAS: 76932-56-4
- KEGG: C07613
- PubChem: 9815
- KNApSAcK: 7445
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- I Leonard Bernstein, David I Bernstein, Zana L Lummus, Jonathan A Bernstein. A case of progesterone-induced anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis.
Journal of women's health (2002).
2011 Apr; 20(4):643-8. doi:
10.1089/jwh.2010.2468. [PMID: 21417747] - S Goericke-Pesch, A Spang, M Schulz, G Ozalp, M Bergmann, C Ludwig, B Hoffmann. Recrudescence of spermatogenesis in the dog following downregulation using a slow release GnRH agonist implant.
Reproduction in domestic animals = Zuchthygiene.
2009 Jul; 44 Suppl 2(?):302-8. doi:
10.1111/j.1439-0531.2009.01378.x. [PMID: 19754591] - S Rubion, P O Desmoulins, E Rivière-Godet, M Kinziger, F Salavert, F Rutten, A Flochlay-Sigognault, M A Driancourt. Treatment with a subcutaneous GnRH agonist containing controlled release device reversibly prevents puberty in bitches.
Theriogenology.
2006 Oct; 66(6-7):1651-4. doi:
10.1016/j.theriogenology.2006.02.015. [PMID: 16564080] - Ming-Huei Cheng, Bill Ken-Jen Yu, Sheng-Ping Chang, Peng-Hui Wang. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan.
Journal of the Chinese Medical Association : JCMA.
2005 Jul; 68(7):307-14. doi:
10.1016/s1726-4901(09)70166-2. [PMID: 16038370] - Muberra Kocak, Aytül Tarcan, Gülay Beydilli, Sevgi Koç, Ali Haberal. Serum levels of prostate-specific antigen and androgens after nasal administration of a gonadotropin releasing hormone-agonist in hirsute women.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
2004 Apr; 18(4):179-85. doi:
10.1080/09513590410001692465. [PMID: 15293888] - JiHyun Suh, EunYoung Lee, SeongSoo Hwang, Sarah Yoon, Byung Koo Yoon, DukSoo Bae, DooSeok Choi. Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle.
European journal of obstetrics, gynecology, and reproductive biology.
2004 Jan; 112(1):65-8. doi:
10.1016/s0301-2115(03)00317-8. [PMID: 14687742] - Wiesław Szymański, Anita Kazdepka-Ziemińska. [Effect of homocysteine concentration in follicular fluid on a degree of oocyte maturity].
Ginekologia polska.
2003 Oct; 74(10):1392-6. doi:
. [PMID: 14669450] - T L Davis, M L Mussard, H Jimenez-Severiano, W J Enright, J E Kinder. Chronic treatment with an agonist of gonadotropin-releasing hormone enhances luteal function in cattle.
Biology of reproduction.
2003 Aug; 69(2):398-403. doi:
10.1095/biolreprod.102.013821. [PMID: 12672667] - J Vanderlelie, K Bell, A V Perkins. The serum concentration of estradiol after embryo transfer and the decline from preovulatory levels may influence the success of IVF treatment.
Hormone research.
2003; 59(2):95-9. doi:
10.1159/000068578. [PMID: 12589114] - Rhoda H Cobin. The case of the elusive androgen.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2002 Nov; 8(6):433-8. doi:
10.4158/ep.8.6.433. [PMID: 15260009] - Anthony P Cheung, Sheila M Pride, Basil Ho Yuen, Lydia Sy. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.
Human reproduction (Oxford, England).
2002 Oct; 17(10):2540-7. doi:
10.1093/humrep/17.10.2540. [PMID: 12351525] - T Strowitzki, B Halser, T Demant. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
2002 Feb; 16(1):45-51. doi:
10.1080/gye.16.1.45.51. [PMID: 11915581] - T Tanaka, N Umesaki, S Ogita. Altered sensitivity to anti-endometriosis medicines in an adenomyosis patient with thyroid dysfunction.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
2000 Oct; 14(5):388-91. doi:
10.3109/09513590009167708. [PMID: 11109979] - T Kurabayashi, K Takakuwa, K Tanaka. Treatment with nafarelin for endometriosis in young women. Efficacy, safety and lipid metabolism. Niigata Nafarelin Study Group.
The Journal of reproductive medicine.
2000 Jun; 45(6):454-60. doi:
NULL. [PMID: 10900577] - M Tahara, T Matsuoka, T Yokoi, K Tasaka, H Kurachi, Y Murata. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ('draw-back' therapy).
Fertility and sterility.
2000 Apr; 73(4):799-804. doi:
10.1016/s0015-0282(99)00636-6. [PMID: 10731543] - A Nakao, H Iwagaki, T Kanagawa, A Jikuhara, N Matsubara, N Takakura, H Isozaki, N Tanaka. Crohn's disease mimicking as bowel endometriosis. Are the symptoms reduced by nafarelin acetate?.
Archives of gynecology and obstetrics.
2000 Feb; 263(3):131-3. doi:
10.1007/s004040050011. [PMID: 10763842] - G E Calvo Lugo, L F Sauceda González, M L Jiménez Perea, F J Díaz Arias. [Treatment of pelvic endometriosis with goserelin acetate or nafarelin acetate. Comparative study].
Ginecologia y obstetricia de Mexico.
2000 Jan; 68(?):7-14. doi:
NULL. [PMID: 10774095] - J S Finkelstein, D A Schoenfeld. Effects of gonadal suppression on the regulation of parathyroid hormone and 1,25-dihydroxyvitamin D secretion in women.
The Journal of clinical endocrinology and metabolism.
1999 Jun; 84(6):2151-6. doi:
10.1210/jcem.84.6.5758. [PMID: 10372724] - H J Out, S Lindenberg, A L Mikkelsen, T Eldar-Geva, D L Healy, A Leader, F J Rodriguez-Escudero, J A Garcia-Velasco, A Pellicer. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.
Human reproduction (Oxford, England).
1999 Mar; 14(3):622-7. doi:
10.1093/humrep/14.3.622. [PMID: 10221686] - N Simberg, M Tulppala, L M Husa, A Tiitinen. Comparison of buserelin and nafarelin in IVF cycles and in subsequent frozen-thawed embryo transfer cycles.
Acta obstetricia et gynecologica Scandinavica.
1998 Sep; 77(8):854-9. doi:
NULL. [PMID: 9776601] - J S Finkelstein, A Klibanski, A L Arnold, T L Toth, M D Hornstein, R M Neer. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.
JAMA.
1998 Sep; 280(12):1067-73. doi:
10.1001/jama.280.12.1067. [PMID: 9757854] - S Sakamoto, T Mitamura, M Iwasawa, H Kitsunai, K Shindou, Y Yagishita, Y F Zhou, S Sassa. Conservative management for perimenopausal women with uterine leiomyomas using Chinese herbal medicines and synthetic analogs of gonadotropin-releasing hormone.
In vivo (Athens, Greece).
1998 May; 12(3):333-7. doi:
". [PMID: 9706480] - A Barash, A Weissman, M Manor, D Milman, A Ben-Arie, Z Shoham. Prospective evaluation of endometrial thickness as a predictor of pituitary down-regulation after gonadotropin-releasing hormone analogue administration in an in vitro fertilization program.
Fertility and sterility.
1998 Mar; 69(3):496-9. doi:
10.1016/s0015-0282(97)00542-6. [PMID: 9531885] - M Taga, H Minaguchi. Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing hormone agonist administration.
European journal of endocrinology.
1997 Aug; 137(2):167-71. doi:
10.1530/eje.0.1370167. [PMID: 9272105] - S Fernandéz-Shaw, S H Kennedy, B R Hicks, K Edmonds, P M Starkey, D H Barlow. Anti-endometrial antibodies in women measured by an enzyme-linked immunosorbent assay.
Human reproduction (Oxford, England).
1996 Jun; 11(6):1180-4. doi:
10.1093/oxfordjournals.humrep.a019351. [PMID: 8671419] - L A Marshall, D F Cain, W P Dmowski, C H Chesnut. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Obstetrics and gynecology.
1996 Mar; 87(3):350-4. doi:
10.1016/0029-7844(95)00424-6. [PMID: 8598953] - M Taga, H Minaguchi. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
Acta obstetricia et gynecologica Scandinavica.
1996 Feb; 75(2):162-5. doi:
10.3109/00016349609033310. [PMID: 8604604] - G B Kletter, A Rolfes-Curl, J C Goodpasture, S B Solish, L Scott, M R Henzl, I Z Beitins. Gonadotropin-releasing hormone agonist analog (nafarelin): a useful diagnostic agent for the distinction of constitutional growth delay from hypogonadotropic hypogonadism.
Journal of pediatric endocrinology & metabolism : JPEM.
1996 Jan; 9(1):9-19. doi:
10.1515/jpem.1996.9.1.9. [PMID: 8887129] - K Ghai, J F Cara, R L Rosenfield. Gonadotropin releasing hormone agonist (nafarelin) test to differentiate gonadotropin deficiency from constitutionally delayed puberty in teen-age boys--a clinical research center study.
The Journal of clinical endocrinology and metabolism.
1995 Oct; 80(10):2980-6. doi:
10.1210/jcem.80.10.7559884. [PMID: 7559884] - K Newhall-Perry, L Holloway, L Osburn, S E Monroe, L Heinrichs, M Henzl, R Marcus. Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.
American journal of obstetrics and gynecology.
1995 Sep; 173(3 Pt 1):824-9. doi:
10.1016/0002-9378(95)90348-8. [PMID: 7573251] - C Schmidt-Sarosi, D R Kaplan, P Sarosi, M N Essig, F L Licciardi, M Keltz, M Levitz. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.
Journal of assisted reproduction and genetics.
1995 Mar; 12(3):167-74. doi:
10.1007/bf02211793. [PMID: 8520180] - T Mizutani, M Sakata, N Terakawa. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat.
International journal of fertility and menopausal studies.
1995 Mar; 40(2):106-11. doi:
NULL. [PMID: 7599657] - A A Yuzpe, J A Nisker, B R Kaplan, I S Tummon, J Auckland. Nafarelin acetate for pituitary down-regulation in in vitro fertilization. Comparison of two dosages.
The Journal of reproductive medicine.
1995 Feb; 40(2):83-8. doi:
NULL. [PMID: 7738933] - G M Lockwood, S M Pinkerton, D H Barlow. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
Human reproduction (Oxford, England).
1995 Feb; 10(2):293-8. doi:
10.1093/oxfordjournals.humrep.a135930. [PMID: 7769051] - P Luppa, B Müller, K Jacob, R Kimmig, T Strowitzki, C Höss, M M Weber, D Engelhardt, R A Lobo. Variations of steroid hormone metabolites in serum and urine in polycystic ovary syndrome after nafarelin stimulation: evidence for an altered corticoid excretion.
The Journal of clinical endocrinology and metabolism.
1995 Jan; 80(1):280-8. doi:
10.1210/jcem.80.1.7829627. [PMID: 7829627] - J S Finkelstein, A Klibanski, E H Schaefer, M D Hornstein, I Schiff, R M Neer. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
The New England journal of medicine.
1994 Dec; 331(24):1618-23. doi:
10.1056/nejm199412153312404. [PMID: 7969342] - R L Rosenfield, R B Barnes, D A Ehrmann. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
The Journal of clinical endocrinology and metabolism.
1994 Dec; 79(6):1686-92. doi:
10.1210/jcem.79.6.7989476. [PMID: 7989476] - C R Givens, E D Schriock, P V Dandekar, M C Martin. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cycles.
Fertility and sterility.
1994 Nov; 62(5):1011-7. doi:
10.1016/s0015-0282(16)57066-6. [PMID: 7926111] - H A Van Leusden. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
1994 Sep; 8(3):215-22. doi:
10.3109/09513599409072458. [PMID: 7847108] - Z N Dantas, M Vicino, J P Balmaceda, R H Asch, S C Stone. Comparison between nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study.
Fertility and sterility.
1994 Apr; 61(4):705-8. doi:
10.1016/s0015-0282(16)56649-7. [PMID: 8150114] - J Jacobson, S R Harris, R E Bullingham. Low dose intranasal nafarelin for the treatment of endometriosis.
Acta obstetricia et gynecologica Scandinavica.
1994 Feb; 73(2):144-50. doi:
10.3109/00016349409013417. [PMID: 8116353] - C E Overton, S H Kennedy, D E Egan, D H Barlow. The effect of nafarelin on human plasma adrenocorticotrophic hormone and cortisol concentrations.
Human reproduction (Oxford, England).
1993 Oct; 8(10):1593-7. doi:
10.1093/oxfordjournals.humrep.a137897. [PMID: 8300812] - P Mahachoklertwattana, S L Kaplan, M M Grumbach. The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: natural history.
The Journal of clinical endocrinology and metabolism.
1993 Jul; 77(1):118-24. doi:
10.1210/jcem.77.1.8325933. [PMID: 8325933] - E M Rutanen, A M Teppo, U H Stenman, A Tiitinen, F Fyhrquist, O Ylikorkala. Recurrent fever associated with progesterone action and persistently elevated serum levels of immunoreactive tumor necrosis factor-alpha and interleukin-6.
The Journal of clinical endocrinology and metabolism.
1993 Jun; 76(6):1594-8. doi:
10.1210/jcem.76.6.7684743. [PMID: 7684743] - S L Corson, F R Batzer, B Gocial, G Maislin. The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of a gonadotropin-releasing hormone agonist.
Fertility and sterility.
1993 Jun; 59(6):1251-6. doi:
10.1016/s0015-0282(16)55985-8. [PMID: 8495774] - R L Rosenfield, D A Ehrmann, R B Barnes, Z Sheikh. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism.
Annals of the New York Academy of Sciences.
1993 May; 687(?):162-81. doi:
10.1111/j.1749-6632.1993.tb43864.x. [PMID: 8323171] - D A Ehrmann, R L Rosenfield, R B Barnes, D F Brigell, Z Sheikh. Detection of functional ovarian hyperandrogenism in women with androgen excess.
The New England journal of medicine.
1992 Jul; 327(3):157-62. doi:
10.1056/nejm199207163270304. [PMID: 1319000] - T Uemura, T Yanagisawa, K Shirasu, A Matsuyama, H Minaguchi. Mechanisms involved in the pituitary desensitization induced by gonadotropin-releasing hormone agonists.
American journal of obstetrics and gynecology.
1992 Jul; 167(1):283-91. doi:
10.1016/s0002-9378(11)91676-7. [PMID: 1332475] - A M Franssen, P F van der Heijden, C M Thomas, W H Doesburg, W N Willemsen, R Rolland. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
Fertility and sterility.
1992 May; 57(5):974-9. doi:
10.1016/s0015-0282(16)55011-0. [PMID: 1533376] - A S Penzias, F N Shamma, J N Gutmann, E E Jones, A H DeCherney, G Lavy. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial.
Obstetrics and gynecology.
1992 May; 79(5 ( Pt 1)):739-42. doi:
NULL. [PMID: 1533022] - NULL. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET).
Fertility and sterility.
1992 Mar; 57(3):514-22. doi:
NULL. [PMID: 1531464] - M D Chaplin. Bioavailability of nafarelin in healthy volunteers.
American journal of obstetrics and gynecology.
1992 Feb; 166(2):762-5. doi:
10.1016/0002-9378(92)91710-r. [PMID: 1531580] - L R Hickok, K A Burry, N L Cohen, D E Moore, K D Dahl, M R Soules. Medical treatment of endometriosis: a comparison of the suppressive effects of danazol and nafarelin on reproductive hormones.
Fertility and sterility.
1991 Oct; 56(4):622-7. doi:
10.1016/s0015-0282(16)54590-7. [PMID: 1833245] - D Hellberg, B Fors, C Bergqvist. Renal endometriosis treated with a gonadotrophin releasing hormone agonist. Case report.
British journal of obstetrics and gynaecology.
1991 Apr; 98(4):406-7. doi:
10.1111/j.1471-0528.1991.tb13434.x. [PMID: 1827737] - J P Weber, P C Walsh, C A Peters, J L Spivak. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men.
American journal of hematology.
1991 Mar; 36(3):190-4. doi:
10.1002/ajh.2830360306. [PMID: 1705094] - O Ylikorkala, C G Nilsson, E Hirvonen, L Viinikka. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
1990 Dec; 4(4):251-60. doi:
10.3109/09513599009024979. [PMID: 2150580] - N A Letassy, D F Thompson, M L Britton, R R Suda. Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis.
DICP : the annals of pharmacotherapy.
1990 Dec; 24(12):1204-9. doi:
10.1177/106002809002401212. [PMID: 2151003] - R W Whitehouse, J E Adams, K Bancroft, C A Vaughan-Williams, M Elstein. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.
Clinical endocrinology.
1990 Sep; 33(3):365-73. doi:
10.1111/j.1365-2265.1990.tb00501.x. [PMID: 2147597] - R A Burns, K Vitale, L M Sanders. Nafarelin controlled release injectable: theoretical clinical plasma profiles from multiple dosing and from mixtures of microspheres containing 2 per cent, 4 per cent and 7 per cent nafarelin.
Journal of microencapsulation.
1990 Jul; 7(3):397-413. doi:
10.3109/02652049009021849. [PMID: 2143531] - D Hartwell, B J Riis, C Christiansen. Changes in vitamin D metabolism during natural and medical menopause.
The Journal of clinical endocrinology and metabolism.
1990 Jul; 71(1):127-32. doi:
10.1210/jcem-71-1-127. [PMID: 2142491] - T Jaakkola, Y Q Ding, P Kellokumpu-Lehtinen, R Valavaara, H Martikainen, J Tapanainen, L Rönnberg, I Huhtaniemi. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
The Journal of clinical endocrinology and metabolism.
1990 Jun; 70(6):1496-505. doi:
10.1210/jcem-70-6-1496. [PMID: 2140831] - B J Riis, C Christiansen, J S Johansen, J Jacobson. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?.
The Journal of clinical endocrinology and metabolism.
1990 Apr; 70(4):920-4. doi:
10.1210/jcem-70-4-920. [PMID: 2138631] - M R Henzl, L Kwei. Efficacy and safety of nafarelin in the treatment of endometriosis.
American journal of obstetrics and gynecology.
1990 Feb; 162(2):570-4. doi:
10.1016/0002-9378(90)90432-7. [PMID: 2137971] - C Bergquist. Effects of nafarelin versus danazol on lipids and calcium metabolism.
American journal of obstetrics and gynecology.
1990 Feb; 162(2):589-91. doi:
10.1016/0002-9378(90)90438-d. [PMID: 2137977] - M Välimäki, C G Nilsson, R Roine, O Ylikorkala. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis.
The Journal of clinical endocrinology and metabolism.
1989 Dec; 69(6):1097-103. doi:
10.1210/jcem-69-6-1097. [PMID: 2531153] - D A Ehrmann, R L Rosenfield, L Cuttler, S Burstein, J F Cara, L L Levitsky. A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies.
The Journal of clinical endocrinology and metabolism.
1989 Nov; 69(5):963-7. doi:
10.1210/jcem-69-5-963. [PMID: 2529266] - I S Fraser, G McCarron, R Markham. Serum CA-125 levels in women with endometriosis.
The Australian & New Zealand journal of obstetrics & gynaecology.
1989 Nov; 29(4):416-20. doi:
10.1111/j.1479-828x.1989.tb01779.x. [PMID: 2534343] - K A Burry, P E Patton, D R Illingworth. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.
American journal of obstetrics and gynecology.
1989 Jun; 160(6):1454-9; discussion 1459. doi:
10.1016/0002-9378(89)90870-3. [PMID: 2525337] - J P Weber, J E Oesterling, C A Peters, A W Partin, D W Chan, P C Walsh. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.
The Journal of urology.
1989 Apr; 141(4):987-92. doi:
10.1016/s0022-5347(17)41083-4. [PMID: 2467015] - R B Barnes, R L Rosenfield, S Burstein, D A Ehrmann. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
The New England journal of medicine.
1989 Mar; 320(9):559-65. doi:
10.1056/nejm198903023200904. [PMID: 2521688] - A Lemay. Clinical appreciation of LHRH analogue formulations.
Hormone research.
1989; 32 Suppl 1(?):93-101; discussion 102. doi:
10.1159/000181319. [PMID: 2533161] - J S Johansen, B J Riis, C Hassager, M Moen, J Jacobson, C Christiansen. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.
The Journal of clinical endocrinology and metabolism.
1988 Oct; 67(4):701-6. doi:
10.1210/jcem-67-4-701. [PMID: 2971080] - R L Chan, M R Henzl, M E LePage, J LaFargue, C A Nerenberg, S Anik, M D Chaplin. Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.
Clinical pharmacology and therapeutics.
1988 Sep; 44(3):275-82. doi:
10.1038/clpt.1988.150. [PMID: 2970910] - B H Vickery, J Powell, V C Stevens. Desensitization of both luteal and pituitary function in baboons with nafarelin, a potent LH-RH agonist.
International journal of fertility.
1988 May; 33(3):188-93. doi:
NULL. [PMID: 2899565] - J C Goodpasture, K Bergstrom, B H Vickery. Potentiation of the gonadotoxicity of Cytoxan in the dog by adjuvant treatment with a luteinizing hormone-releasing hormone agonist.
Cancer research.
1988 Apr; 48(8):2174-8. doi:
NULL. [PMID: 2964898] - J L Andreyko, Z Blumenfeld, L A Marshall, S E Monroe, H Hricak, R B Jaffe. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
American journal of obstetrics and gynecology.
1988 Apr; 158(4):903-10. doi:
10.1016/0002-9378(88)90092-0. [PMID: 2966587] - C A Peters, P C Walsh. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
The New England journal of medicine.
1987 Sep; 317(10):599-604. doi:
10.1056/nejm198709033171004. [PMID: 2441256] - G F Weinbauer, M Respondek, H Themann, E Nieschlag. Reversibility of long-term effects of GnRH agonist administration on testicular histology and sperm production in the nonhuman primate.
Journal of andrology.
1987 Sep; 8(5):319-29. doi:
10.1002/j.1939-4640.1987.tb00970.x. [PMID: 2959641] - J A Gudmundsson, S Ljunghall, C Bergquist, L Wide, S J Nillius. Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition.
The Journal of clinical endocrinology and metabolism.
1987 Jul; 65(1):159-63. doi:
10.1210/jcem-65-1-159. [PMID: 2953749] - R M Eley. The effect of LHRH analogs on pregnancy in the baboon.
Contraception.
1987 Apr; 35(4):389-93. doi:
10.1016/0010-7824(87)90075-8. [PMID: 2957166] - P G Hoffman, M R Henzl, M D Chaplin, C A Nerenberg. Clinical development of nafarelin acetate. Phase I and phase II studies.
Journal of andrology.
1987 Jan; 8(1):S17-22. doi:
NULL. [PMID: 2951357] - R L Rosenfield, L R Garibaldi, G W Moll, A C Watson, S Burstein. The rapid ovarian secretory response to pituitary stimulation by the gonadotropin-releasing hormone agonist nafarelin in sexual precocity.
The Journal of clinical endocrinology and metabolism.
1986 Dec; 63(6):1386-9. doi:
10.1210/jcem-63-6-1386. [PMID: 2946712] - S E Monroe, Z Blumenfeld, J L Andreyko, E Schriock, M R Henzl, R B Jaffe. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).
The Journal of clinical endocrinology and metabolism.
1986 Dec; 63(6):1334-41. doi:
10.1210/jcem-63-6-1334. [PMID: 2946710] - J L Andreyko, S E Monroe, R B Jaffe. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
The Journal of clinical endocrinology and metabolism.
1986 Oct; 63(4):854-9. doi:
10.1210/jcem-63-4-854. [PMID: 2943756] - J A Gudmundsson, S J Nillius, C Bergquist. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Fertility and sterility.
1986 May; 45(5):617-23. doi:
10.1016/s0015-0282(16)49331-3. [PMID: 2938984] - J A Gudmundsson, C Bergquist, S J Nillius. Peptide contraception by inhibition of ovulation with intranasal GnRH superagonist: clinical and metabolic aspects.
Progress in clinical and biological research.
1986; 225(?):337-51. doi:
NULL. [PMID: 2947248] - P F Brenner, D Shoupe, D R Mishell. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Contraception.
1985 Dec; 32(6):531-51. doi:
10.1016/s0010-7824(85)80001-9. [PMID: 2936564] - R S Swerdloff, D J Handelsman, S Bhasin. Hormonal effects of GnRH agonist in the human male: an approach to male contraception using combined androgen and GnRH agonist treatment.
Journal of steroid biochemistry.
1985 Nov; 23(5B):855-61. doi:
10.1016/s0022-4731(85)80027-3. [PMID: 2934582] - E Schriock, S E Monroe, M Henzl, R B Jaffe. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin).
Fertility and sterility.
1985 Nov; 44(5):583-8. doi:
10.1016/s0015-0282(16)48970-3. [PMID: 2932349] - R S Chiang, R B Barnes, D Shoupe, R A Lobo. Dose-related changes in LH bioactivity with intranasal GnRH agonist administration.
Contraception.
1985 Oct; 32(4):347-57. doi:
10.1016/0010-7824(85)90038-1. [PMID: 2934222] - N I Chu, R L Chan, K M Hama, M D Chaplin. Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.
Drug metabolism and disposition: the biological fate of chemicals.
1985 Sep; 13(5):560-5. doi:
NULL. [PMID: 2865103] - R L Chan, M D Chaplin. Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey.
Drug metabolism and disposition: the biological fate of chemicals.
1985 Sep; 13(5):566-71. doi:
NULL. [PMID: 2865104] - G I McRae, B B Roberts, A C Worden, A Bajka, B H Vickery. Long-term reversible suppression of oestrus in bitches with nafarelin acetate, a potent LHRH agonist.
Journal of reproduction and fertility.
1985 Jul; 74(2):389-97. doi:
10.1530/jrf.0.0740389. [PMID: 2931517] - E D Schriock, S E Monroe, M C Martin, M R Henzl, R B Jaffe. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).
Fertility and sterility.
1985 Jun; 43(6):844-50. doi:
10.1016/s0015-0282(16)48610-3. [PMID: 3158549] - R L Chan, M D Chaplin. Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist.
Biochemical and biophysical research communications.
1985 Mar; 127(2):673-9. doi:
10.1016/s0006-291x(85)80214-x. [PMID: 3156598] - S E Monroe, M R Henzl, M C Martin, E Schriock, V Lewis, C Nerenberg, R B Jaffe. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.
Fertility and sterility.
1985 Mar; 43(3):361-8. doi:
10.1016/s0015-0282(16)48432-3. [PMID: 3156770] - C Weil, L W Crim. Manipulation of the hypothalamo-pituitary gonadal axis in the juvenile rainbow trout: influence of pituitary transplantation and LHRH analogue treatment.
Reproduction, nutrition, developpement.
1985; 25(5):895-907. doi:
10.1051/rnd:19850706. [PMID: 2934776] - C Nerenberg, J Foreman, N Chu, M D Chaplin, S Kushinsky. Radioimmunoassay of nafarelin ([ 6-(3-(2-naphthyl)-D-alanine)]-luteinizing hormone-releasing hormone) in plasma or serum.
Analytical biochemistry.
1984 Aug; 141(1):10-6. doi:
10.1016/0003-2697(84)90418-4. [PMID: 6238549] - D Heber, S Bhasin, B Steiner, R S Swerdloff. The stimulatory and down-regulatory effects of a gonadotropin-releasing hormone agonist in man.
The Journal of clinical endocrinology and metabolism.
1984 Jun; 58(6):1084-8. doi:
10.1210/jcem-58-6-1084. [PMID: 6233295]